Lloyd Park’s Novo Nordisk NVO Stock Holding History

Lloyd Park’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,810	Closed	-$272K	–	88
2022 Q1	$272K	Buy	+4,810	New	+$247K	0.3%	54

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lloyd Park's NVO Position: Q2 2022 in Review

Lloyd Park sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 4,810 shares — an estimated $272K sold.

Lloyd Park first reported a position in NVO in Q1 2022 and held it in 1 quarter. The position peaked at $272K in Q1 2022. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

Lloyd Park reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
Lloyd Park sold 4,810 Novo Nordisk shares in Q2 2022, an estimated $272K.
Lloyd Park first reported a position in Novo Nordisk in Q1 2022 and held it in 1 quarter.
Lloyd Park's Novo Nordisk position peaked at $272K in Q1 2022.
932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on Lloyd Park's 13F filing for Q2 2022, filed 9 Aug 2022.